Age and gender adjusted low serum apolipoprotein A1, high C-reactive protein as predisposing biomarkers of SARS-CoV-2 infection. A large retrospective study using UK biobank.
Approved Research ID: 79974
Approval date: March 18th 2022
The aim of this project is to validate a blood based risk stratification tool, combining existing and routinely available markers (apolipoprotein-a1, C-reactive protein) with age and gender that could be an additional diagnosis and prognosis tool for screening subjects at high-risk of SARS-Cov-2 infection (SI).
The 2 biomarkers have a published role in the SARS-Cov-2 infection, with normal values depending on age and gender. A score combining the values of the 2 assays, corrected by age and gender, will be correlated to the risk of SI.
The project will last 3 years.
The public health impact could be major, helping the clinicians stratifying the patients according to this novel risk score.
There is an unmet need for biomarkers that detect the risk of SARS-CoV2 infection (SI) before the exposure. The aim of this research is to use both apolipoprotein A1(A1) and C-reactive protein (CRP) as predisposing biomarkers, adjusted by age, gender, T2-diabetes, BMI and glucose, to estimate the risk of SI.
There is an unmet need for biomarkers that detect the susceptibility of SARS-CoV2 infection (SI) or mortality from COVID-19. The aim of this research is to use both NMR biomarkers (incl. apolipoprotein A1(A1)), C-reactive protein (CRP), Total Bilirubin, genetic marker of Gilbert Syndrome as predisposing biomarkers, adjusted by age, gender, history of liver disease, T2-diabetes, BMI, alcohol consumption, and glucose, to estimate the susceptibility to SI and mortality.